RESEARCH USE ONLY

Premium Research Peptides.​

UK-based supplier of high-purity research peptides, supporting laboratories and researchers across Europe.

At Peptide Amino Group, we are committed to providing reliable access to premium research compounds through collaboration with trusted European and Global laboratories and specialist suppliers. 

Every product is sourced with a focus on quality, transparency, and regulatory compliance, ensuring researchers receive materials they can rely on.

UK Headquarters
European Supply
Quality Focused
Research Use Only
UK Headquarters
European Supply
Quality Focused
Research Use Only
UK Headquarters
European Supply
Quality Focused
Research Use Only

Welcome to Peptide Amino Group

AGE VERIFICATION

Access to peptideaminogroup.com and the purchase of any products listed herein are strictly restricted to authorized researchers, laboratory personnel, and qualified individuals aged 18 years or older.

RESEARCH USE ONLY (RUO) NOTICE: All compounds, reagents, and peptides offered by Peptide Amino Group are supplied strictly for in vitro laboratory research, scientific evaluation, and analytical testing purposes. We make no medical or health claims regarding these products.

THE PRODUCTS OFFERED ON THIS WEBSITE ARE NOT FOR HUMAN OR ANIMAL USE.

Peptide Reconstitution & Storage Guide

Reconstitution is the process of adding a suitable solvent to a lyophilised peptide to prepare a solution for laboratory research. Correct preparation, handling and storage help protect peptide stability.

View Reconstitution & Storage Guide

Best Selling Peptide Stacks

Academic Research

Peer-Reviewed Research

Explore Evidence-Based Peptide Science

Access our curated, indexed database of clinical trials, journal publications, and mechanistic studies across 9+ research categories.

35+ Clinical Studies
9+ Categories
100% Peer-Reviewed
Live Library Preview
Metabolic & Incretin Phase III RCT

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

N Engl J Med (2022) • Jastreboff AM, et al.

  • Dual GLP-1/GIP agonist achieved dose-dependent mean weight reductions up to 20.9% (15 mg dose) at week 72.
Shopping Basket